BioPharma Resources

Investigational drug · Phase 3

CHO Cell

Also called: recombinant zoster vaccine, Recombinant Respiratory Syncytial Virus Vaccine, CHO cells, Recombinant Herpes Zoster Vaccine, Recombinant Zoster Vaccine SYS6052, 0 and 30 days schedule, 0 and 60 days schedule

Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Herpes Zoster, Respiratory Syncytial Virus (RSV), Herpes Zoster (HZ).

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

9

7 still active

All registered trials

119

Any phase or sponsor naming "CHO Cell"

First trial start

2023

May 7, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "CHO Cell", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Herpes Zoster
  • Respiratory Syncytial Virus (RSV)
  • Herpes Zoster (HZ)

Approved drugs for the same conditions: RSV · Herpes and shingles · Infectious disease and vaccines

Largest trials

Live from ClinicalTrials.gov: studies naming "CHO Cell" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 17,162 on PubMed

Also in development for Herpes Zoster

  • Sinovac Biotech Co., Ltd · Epidemic Meningitis, Meningococcal Vaccines, Herpes Zoster

  • su vaccineRZVPhase 32 trials

    GSK · Herpes Zoster, Respiratory Syncytial Virus (RSV)

  • SCTV04CRecombinant Herpes Zoster Vaccine -DosePhase 21 trial

    Sinocelltech Ltd. · Herpes Zoster

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.